Medical News

RSS

New palate reconstruction technique for post tonsil cancer surgery

A new technique for reconstructing the palate after surgery for tonsil cancer maintained patients' ability to speak clearly and eat most foods, a new study shows.

23 Sep 2009

ART's new generation Optix MX3 optical molecular imaging system unveiled

ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today unveiled a new generation of its optical molecular imaging system, called Optix® MX3, at the Industry Workshop opening event of the World Molecular Imaging Congress.

23 Sep 2009

Interleukin Genetics reports positive results from clinical study on weight management

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today top-line positive results from a retrospective clinical study on weight management using patients who participated in a diet study previously reported in the Journal of the American Medical Association.

23 Sep 2009

NASDAQ halts trading in CombinatoRx's common stock

CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company’s common stock today.

23 Sep 2009

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.

23 Sep 2009

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

23 Sep 2009

Congressional Black Caucus Spouses to host 4th Annual Community Health Breakfast

On September 24, 2009, the Congressional Black Caucus Spouses will continue their tradition of direct community involvement by hosting its 4th Annual Community Health Breakfast at So Others Might Eat (SOME) from 7 a.m. - 10:30 a.m., 71 O Street, NW, Washington, D.C.

23 Sep 2009

ID Analytics' risk management solutions available on U.S. GSA Schedule

ID Analytics, Inc., the leader in on-demand identity intelligence, announced today its risk management solutions are now available on its' U.S. General Services Administration (GSA) Schedule.

23 Sep 2009

OMA's first ever media campaign to focus on the issue of patient safety

The Ontario Medical Association (OMA) Section on General & Family Practice (SGFP) held a media conference today to announce the launch of its first ever media campaign.

23 Sep 2009

Pluristem commences dosing in Phase I clinical trial for the treatment of critical limb ischemia

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

23 Sep 2009

Adolor acquires exclusive worldwide rights to OpRA III

Adolor Corporation (NasdaqGM:ADLR) today announced that it has acquired from Eli Lilly and Company (“Lilly”) the exclusive worldwide rights to OpRA III, a clinical-stage product candidate.

23 Sep 2009

First Edition: September 23, 2009

Today's headlines mark the opening day of the Senate Finance Committee's health bill mark up as well as a new round up of changes to the chairman's mark.

23 Sep 2009

Clinical informatics solution for health care providers and pharmaceutical firms

Humedica, a next-generation health care informatics company, today announced the company’s official launch, along with the previous completion of its $30 million round of venture capital and the roll-out of its ground-breaking clinical analytics platform.

23 Sep 2009

Cannabis Science to feature in two broadcast radio shows

Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report that it will be featured on two broadcast radio shows beginning tomorrow with Stu Taylor and the “Equity Strategies Show”. Mr. Taylor will interview Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., discussing the Company’s strategies with its FDA Drug approval programs, the Company’s progress to date with its critical drug release programs, and future planning for subsequent drug releases through additional Federal and State government agencies.

23 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

23 Sep 2009

Dr. John Clarke polls more than 50,000 votes to win the 2009 H1N1 PSA contest

Department of Health and Human Services (HHS) Secretary Sebelius and Department of Education (ED) Secretary Arne Duncan today announced that Dr. John Clarke of Baldwin, N.Y., is the winner of the 2009 H1N1 PSA Contest. More than 50,000 votes were cast by Americans across the country on YouTube. Dr. Clarke will receive a $2,500 cash prize and his ad will be broadcast on national television.

23 Sep 2009

Improved respiratory health in Mexican women who use vented stoves

Women in Central Mexico who used a vented stove instead of the traditional indoor open fire, experienced improved respiratory health on par with a pack-a-day smoker kicking the habit, according to a recent study.

23 Sep 2009

Organic revitalizing beverage from Sambazon

Sambazon, the global leader in Acai, announces the launch of a powerfully nutritious premium juice line. Antioxidant Elixir(TM) is a organic revitalizing beverage that provides powerful antioxidants and 600% DV Vitamin C, yet remains refreshingly light on calories, sugar, and contains no fat.

23 Sep 2009